Boxplots of DNA and RNA Purification yields from MFC sorted samples grouped by patient group or sample type are shown in Figure S1 . Figure S1. DNA (panels (a) and (c)) and RNA (panels (b) and (d)) yields from MFC sorted samples divided into different patient groups (panels (a) and (b)) or sample types (panels (c) and (d)). The pvalues indicate, whether the mean values are equal among all groups (by one-way ANOVA). If multiple fractions were collected after sorting, only the sequenced one is represented in the figure.
. Variant interpretation results. The highest clinical assessment in each of the three categories; overall, therapeutic, and prognostic and the corresponding gene(s) of each sample subjected to variant interpretation is given. The MSI status and TMB for each sample is also shown. NA = Sample did not have a gene with a clinical relevance ≥ 2. Explanation of each Criteria ID is given in the sheet Value explanation. * TMB is given as no. mutations/Mb. ** MSI status is given as percentage of instable microsatellites. 1A-S1 = Biomarker predicts a response to FDA, EMA or PMDA approved therapies for this diagnosis, 1A-S2 = Biomarker included in professional guidelines is predictive of response to FDA, EMA or PMDA approved therapies for this diagnosis, 1A-R1 = Biomarker predicts resistance to FDA, EMA or PMDA approved therapies for this diagnosis, 1A-R2 = Biomarker included in professional guidelines is predictive of resistance to FDA, EMA or PMDA approved therapies for this diagnosis, 1B-S = Biomarker predicts a response to therapies for this diagnosis based on well-powered studies, 1B-R = Biomarker predicts resistance to therapies for this diagnosis based on well-powered studies, 1A-P = Biomarker included in professional guidelines is prognostic for this diagnosis, 1B-P = Biomarker is prognostic for this diagnosis based on well-powered studies, 1A-D = Biomarker included in professional guidelines is diagnostic for this diagnosis, 1B-D = Biomarker is diagnostic for this diagnosis based on well-powered studies, 2C-S1 = Biomarker is associated with response to FDA, EMA or PMDA approved therapies for a different diagnosis, 2C-S2 = Biomarker included in professional guidelines is associated with response to FDA, EMA or PMDA approved therapies for a different diagnosis, 2C-R1 = Biomarker is associated with resistance to FDA, EMA or PMDA approved therapies for a different diagnosis, 2C-R2 = Biomarker included in professional guidelines is associated with resistance to FDA, EMA or PMDA approved therapies for a different diagnosis, 2C-CT = Biomarker serves as an inclusion criterion for one or more clinical trials, 2D-S = Biomarker shows plausible response based on case studies, 2D-R = Biomarker shows plausible response based on case studies, 2C-P = Biomarker is prognostic based on multiple small studies, 2D-P = Biomarker is plausibly prognostic for this diagnosis based on case studies, 2C-D = Biomarker is diagnostic based on multiple small studies, 2D-D = Biomarker is plausibly diagnostic for this diagnosis based on case studies, 3 = Biomarker has uncertain clinical significance and not known to be likely benign or benign, 4 = Biomarker is classified as likely benign based on the ACMG/AMP guidelines.
